Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 8, Issue 3, Pages 354
Publisher
MDPI AG
Online
2019-03-14
DOI
10.3390/jcm8030354
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor necrosis factor-α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation
- (2018) Aerken Maolake et al. CANCER SCIENCE
- C-C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment
- (2018) Satoko Urata et al. CANCER SCIENCE
- Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
- (2018) Kazuaki Machioka et al. Oncotarget
- CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
- (2018) Ariunbold Natsagdorj et al. CANCER SCIENCE
- Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells
- (2018) Hiroaki Iwamoto et al. PROSTATE
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment
- (2016) Chiuan-Ren Yeh et al. Molecular Cancer
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis
- (2016) Aerken Maolake et al. Oncotarget
- Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic Inflammation
- (2016) Francesca Barone et al. Frontiers in Immunology
- The β-catenin signaling pathway induces aggressive potential in breast cancer by up-regulating the chemokine CCL5
- (2015) Rika Yasuhara et al. EXPERIMENTAL CELL RESEARCH
- Synthesis, binding affinity and structure–activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists
- (2015) Anna Junker et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals
- (2015) Jie Luo et al. Oncotarget
- Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer
- (2015) Kouji Izumi et al. Oncotarget
- The Chemokine CCL2 Increases Prostate Tumor Growth and Bone Metastasis through Macrophage and Osteoclast Recruitment
- (2015) Kosuke Mizutani et al. NEOPLASIA
- Design and synthesis of novel small molecule CCR2 antagonists: Evaluation of 4-aminopiperidine derivatives
- (2014) M. Vilums et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation
- (2014) Simona Hefetz-Sela et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Infiltrating Macrophages Promote Prostate Tumorigenesis via Modulating Androgen Receptor-Mediated CCL4-STAT3 Signaling
- (2013) L.-Y. Fang et al. CANCER RESEARCH
- CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling
- (2013) Taku Kato et al. CYTOKINE
- Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation
- (2013) Kouji Izumi et al. EMBO Molecular Medicine
- Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling
- (2013) J Luo et al. ONCOGENE
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
- (2013) T-H Lin et al. Cell Death & Disease
- Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
- (2012) Kenneth J. Pienta et al. INVESTIGATIONAL NEW DRUGS
- Androgen Deprivation Causes Epithelial-Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy
- (2011) Y. Sun et al. CANCER RESEARCH
- Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
- (2011) Peter Friedl et al. CELL
- N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells
- (2011) Arun Kumar Nalla et al. EXPERIMENTAL CELL RESEARCH
- TNF Is Necessary for Castration-Induced Prostate Regression, Whereas TRAIL and FasL Are Dispensable
- (2011) Jennifer S. Davis et al. MOLECULAR ENDOCRINOLOGY
- Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
- (2010) M. Yamaoka et al. CLINICAL CANCER RESEARCH
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma
- (2010) Kazuhito Yamamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
- (2010) Li Yang et al. TRENDS IN IMMUNOLOGY
- A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone
- (2009) Xin Li et al. CANCER RESEARCH
- Breast Cancer Lung Metastasis Requires Expression of Chemokine Receptor CCR4 and Regulatory T Cells
- (2009) P. B. Olkhanud et al. CANCER RESEARCH
- Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor β1-associated osteoblastic changes
- (2009) Kouji Izumi et al. PROSTATE
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
- Stat3 Promotes Metastatic Progression of Prostate Cancer
- (2008) Junaid Abdulghani et al. AMERICAN JOURNAL OF PATHOLOGY
- The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer
- (2008) Stephen J. Assinder et al. BIOCHEMICAL JOURNAL
- CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation
- (2008) Hernan Roca et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Androgen receptor is a tumor suppressor and proliferator in prostate cancer
- (2008) Y. Niu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started